Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, \>=70 years of age or with ECOG PS of 2;
advanced (stage IIIB or IV)non-small cell lung cancer;
no prior systemic chemotherapy for advanced NSCLC or prior treatment with HER-axis targeted drugs.
You may not be if
active brain metastasis or spinal cord suppression;
unstable systemic disease.
Clareo Health | A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
